910 Douglas Pike, Smithfield, RI 02917: 1-800-963-1001: nhpri.org

Hemophilia Products – Factor X: Coagadex

(Intravenous)

Effective date: 10/1/2019

Review date: 1/29/2020, 7/15/2021, 6/16/2022, 6/22/2023, 12/07/2023, 01/04/2024

Scope: Medicaid*, Commercial*, Medicare-Medicaid Plan (MMP)

*(Medication only available on the Medical Benefit)

I. Length of Authorization

Unless otherwise specified*, the initial authorization will be provided for 3 months and may be renewed.

<u>Note</u>: The cumulative amount of medication the patient has on-hand will be taken into account for authorizations. Up to 5 'on-hand' doses for the treatment of acute bleeding episodes will be permitted at the time of the authorization request.

II. Dosing Limits

A. Quantity Limit (max daily dose) [Pharmacy Benefit]:

- Coagadex 250 IU vial: 36 vials per 7 days
- Coagadex 500 IU vial: 18 vials per 7 days

B. Max Units (per dose and over time) [Medical Benefit]:

• 36,800 billable units per 28 day supply

III. Summary of Evidence

Clinical trials have demonstrated the efficacy and safety of factor X replacement therapy in the management of bleeding episodes in patients with congenital factor X deficiency. These therapies provide exogenous factor X activity, facilitating hemostasis and reducing the severity and duration of bleeding episodes. The most common adverse drug reactions observed in clinical trials were infusion site erythema, infusion site pain, fatigue, and back pain.


IV. Initial Approval Criteria

Hemophilia Management Program

Requirements for half-life study and inhibitor tests are a part of the hemophilia management program. This information is not meant to replace clinical decision making when initiating or modifying medication therapy and should only be used as a guide.

A. Coagadex

^{*} Initial and renewal authorization periods may vary by specific covered indication





Coverage is provided in the following conditions:

• MMP members who have previously received this medication within the past 365 days are not subject to Step Therapy Requirements.

Hereditary Factor X deficiency † Φ

- Diagnosis of congenital factor X deficiency has been confirmed by blood coagulation testing; AND
- Used as treatment in one of the following:
 - On-demand treatment and control of bleeding episodes; **OR**
 - o Routine prophylaxis to reduce the frequency of bleeding episodes; AND
 - Patient must have severe factor X deficiency (factor X level of <1%); OR
 - Patient has at least two documented episodes of spontaneous bleeding into joints;
 OR
 - Perioperative management of surgical bleeding in patients with mild deficiency (*Authorizations valid for 1 month)

Hemophilia Management Program

- If the request is for prophylaxis and the requested dose exceeds dosing limits under part II, a half-life study should be performed to determine the appropriate dose and dosing interval.
- For members with a BMI ≥ 30, a half-life study should be performed to determine the appropriate dose and dosing interval.
- For minimally treated patients (< 50 exposure days to factor products) previously receiving a different factor product, inhibitor testing is required at, then at every comprehensive care visit (yearly for the mild and moderate patients, semi-annually for the severe patients).

† FDA Approved Indication(s) **Φ** Orphan Drug

V. Dispensing Requirements for Rendering Providers (Hemophilia Management Program)

- Prescriptions cannot be filled without an expressed need from the patient, caregiver or prescribing practitioner. Auto-filling is not allowed.
- Monthly, rendering provider must submit for authorization of dispensing quantity before delivering factor product. Information submitted must include:
 - Original prescription information, requested amount to be dispensed, vial sizes available to be ordered from the manufacturer, and patient clinical history (including patient product inventory and bleed history)
 - Factor dose should not exceed +1% of the prescribed dose and a maximum of three vials may be dispensed per dose. If unable to provide factor dosing within the required threshold, below the required threshold, the lowest possible dose able to be achieved above +1% should be dispensed. Prescribed dose should not be increased to meet assay management requirements.



- The cumulative amount of medication(s) the patient has on-hand should be taken into account when dispensing factor product. Patients should not have more than 5 extra doses on-hand for the treatment of acute bleeding episodes.
- Dispensing requirements for renderings providers are a part of the hemophilia management program. This
 information is not meant to replace clinical decision making when initiating or modifying medication therapy
 and should only be used as a guide.

VI. Renewal Criteria

Coverage can be renewed based upon the following criteria:

- Patient continues to meet criteria identified in section III; AND
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: symptoms of allergic-anaphylactic reactions (anaphylaxis, dyspnea, rash, etc.), thromboembolic events (thromboembolism, pulmonary embolism), development of neutralizing antibodies (inhibitors), etc.; AND
- Any increases in dose must be supported by an acceptable clinical rationale (i.e., weight gain, half-life study
 results, increase in breakthrough bleeding when patient is fully adherent to therapy, etc.); AND
- The cumulative amount of medication(s) the patient has on-hand will be taken into account when authorizing.
 The authorization will allow up to 5 doses on-hand for the treatment of acute bleeding episodes as needed for the duration of the authorization; AND

On-demand treatment of bleeding episodes and control of bleeding episodes

• Renewals will be approved for a 6 month authorization period

Perioperative management of surgical bleeding

Coverage may NOT be renewed

Routine prophylaxis to reduce the frequency of bleeding episodes

- Renewals will be approved for a 6 month authorization period; AND
- Patient has demonstrated a beneficial response to therapy (i.e., the frequency of bleeding episodes has decreased from pre-treatment baseline)

VII. Dosage/Administration

Coagadex

Indication	Dose
On-demand treatment and control of bleeding	 Children (<12 years of age): 30 IU/kg at first sign of bleeding, repeat every 24 hours until bleeding stops.



Indication	Dose
episodes due to Factor X deficiency	 Adults and adolescents (≥12 years of age): 25 IU/kg at first sign of bleeding, repeat every 24 hours until bleeding stops.
	*Do not administer more than 60 IU/kg daily.
Perioperative management of bleeding in patients with mild and	Do not administer more than 60 IU/kg daily. Pre-surgery:
moderate Factor X	Calculate the dose to raise plasma Factor X levels to 70-90 IU/dL using the formula:
deficiency	Children (<12 years of age): Dose (IU) = Body Weight (kg) x Desired Factor X Rise (IU/dL) x 0.6 (The dosing formula is based on observed recovery of 1.7 IU/dL per IU/kg).
	Adults & adolescents (≥12 years of age): Dose (IU) = Body Weight (kg) x Desired Factor X Rise (IU/dL) x 0.5 (The dosing formula is based on observed recovery of 2 IU/dL per IU/kg).
	Post-surgery:
	Repeat dose as necessary to maintain plasma Factor X levels at a minimum of 50 IU/dL until the patient is no longer at risk of bleeding due to surgery
Prophylaxis of bleeding episodes	 Children (Less than 12 years of age): 40 IU/kg twice weekly Adults and adolescents (12 years of age or older): 25 IU/kg twice weekly
	Monitor trough blood levels of Factor X targeting ≥5 IU/dL and adjust dosage to clinical response and trough levels. Do not exceed a peak level of 120 IU/dL.

VIII. Billing Code/Availability Information

<u>Icode & NDC:</u>

Drug	Manufacturer	J-Code	1 Billable Unit Equiv.	Vial Size	NDC
	Bio Products Laboratory	J7175	1 IU	250 units	- 64208-7752
Coagadex				500 units	- 64208-7753

IX. References

- 1. Coagadex [package insert]. Durham, NC; Bio Products Laboratory; April 2023; Accessed November 2023.
- MASAC RECOMMENDATIONS CONCERNING PRODUCTS LICENSED FOR THE TREATMENT OF HEMOPHILIA AND OTHER BLEEDING DISORDERS. 2016 National Hemophilia Foundation. MASAC Document #249; October 2016. Available at: http://www.hemophilia.org. Accessed January 2019.
- 3. Guidelines for the Management of Hemophilia. 2nd Edition. World Federation of Hemophilia. 2013. Available at: https://www1.wfh.org/publication/files/pdf-1472.pdf. Accessed January 2019.
- 4. Annual Review of Factor Replacement Products. Oklahoma Health Care Authority Review Board. Updated April 2016. Access January 2019.
- 5. Graham A1, Jaworski K. Pharmacokinetic analysis of anti-hemophilic factor in the obese patient. Haemophilia. 2014 Mar;20(2):226-9.



- Croteau SE1, Neufeld EJ. Transition considerations for extended half-life factor products. Haemophilia. 2015 May;21(3):285-8.
- 7. Mingot-Castellano, et al. Application of Pharmacokinetics Programs in Optimization of Haemostatic Treatment in Severe Hemophilia a Patients: Changes in Consumption, Clinical Outcomes and Quality of Life. Blood. 2014 December; 124 (21).
- 8. MASAC RECOMMENDATION CONCERNING PROPHYLAXIS. 2016 National Hemophilia Foundation. MASAC Document #241; February 2016. Available at: http://www.hemophilia.org. Accessed January 2019.
- 9. Brown DL, Kouides PA. Diagnosis and treatment of inherited factor X deficiency. Haemophilia. 2008 Nov;14(6):1176-82
- First Coast Service Options, Inc. Local Coverage Determination (LCD): Hemophilia Clotting Factors (L33684). Centers for Medicare & Medicaid Services, Inc. Updated on 01/04/2019 with effective date 01/01/2019. Accessed January 2019.
- 11. Novitas Solutions, Inc. Local Coverage Determination (LCD): Hemophilia Clotting Factors (L35111). Centers for Medicare & Medicaid Services, Inc. Updated on 01/19/2018 with effective date 01/01/2018. Accessed January 2019.

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description	
D68.2	Hereditary deficiency of other clotting factors	

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Articles (LCAs) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: https://www.cms.gov/medicare-coverage-database/search.aspx. Additional indications may be covered at the discretion of the health plan.


Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCA/LCD):

Jurisdiction(s): J,M	NCD/LCD Document (s): A56065	
https://www.cms.gov/medicare-coverage-database/new-search/search-		
results.aspx?keyword=a56065&areaId=all&docType=NCA%2CCAL%2CNCD%2CMEDCAC%2CTA%2CMCD%2CMCMCDCMCTMCCMCMCMCMCTMCCMCTTTTTTTTTTTT		
<u>C6%2C3%2C5%2C1%2CF%2CP</u>		

Jurisdiction	(s): H,L	NCD/LCD Document (s): A56433

https://www.cms.gov/medicare-coverage-database/new-search/search-

results.aspx?keyword=a56433&areaId=all&docType=NCA%2CCAL%2CNCD%2CMEDCAC%2CTA%2CMCD%2C6%2C3%2C5%2C1%2CF%2CP





	Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor	
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC	
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC	
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)	
6	MN, WI, IL	National Government Services, Inc. (NGS)	
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.	
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)	
N (9)	FL, PR, VI	First Coast Service Options, Inc.	
J (10)	TN, GA, AL	Palmetto GBA, LLC	
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC	
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.	
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)	
15	KY, OH	CGS Administrators, LLC	

Policy Rationale:

Coagadex was reviewed by the Neighborhood Health Plan of Rhode Island Pharmacy & Therapeutics (P&T) Committee. Neighborhood adopted the following clinical coverage criteria to ensure that its members use Coagadex according to Food and Drug Administration (FDA) approved labeling and/or relevant clinical literature. Neighborhood worked with network prescribers and pharmacists to draft these criteria. These criteria will help ensure its members are using this drug for a medically accepted indication, while minimizing the risk for adverse effects and ensuring more cost-effective options are used first, if applicable and appropriate. For INTEGRITY (Medicare-Medicaid Plan) members, these coverage criteria will only apply in the absence of National Coverage Determination (NCD) or Local Coverage Determination (LCD) criteria. Neighborhood will give individual consideration to each request it reviews based on the information submitted by the prescriber and other information available to the plan.